Anti-CD27 (varlilumab biosimilar) mAb
Preservative: 0.1% Procline 300
Constituents: 50% Glycerol; PBS, pH 7.4; 0.1% BSA
|Guarantee||12 months from date of dispatch|
|Package||50 μl $80.00 ; 100 μl $160.00|
|Synonyms||CD27, TNFRSF7, S152, T14, Tp55|
|Host Species||Homo sapiens|
|Purification||Purified from cell culture supernatant by affinity chromatography|
|Recommended Dilutions||ELISA 1:5000-10000|
|Storage||Store at -20°C (Avoid repeated freezing and thawing)|
|Usage||Research use only|
Figure 1. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human CD27, hFc tagged protein (PME100475) can bind Anti-CD27 Neutralizing antibody in a linear range of 3.2-80.0 ng/ml.
Figure 2. ELISA plate pre-coated by 2 μg/ml (100 μl/well) Human CD27, mFc-His tagged protein (PME100013) can bind Anti-CD27 Neutralizing antibody in a linear range of 0.64-16.0 ng/ml.
Figure 3. HEK293 cell line transfected with irrelevant protein (B) and human CD27 protein (A) were surface stained with anti-CD27 neutralizing antibody 1μg/ml (varlilumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.
|Background||Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.|